IGC Pharma, Inc. (FRA:IGS1)
Germany · Delayed Price · Currency is EUR | Market Cap | 28.65M +45.3% |
| Revenue (ttm) | 942.64K -6.5% |
| Net Income | -5.49M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 122 |
| Open | 0.2840 |
| Previous Close | 0.2920 |
| Day's Range | 0.2840 - 0.2840 |
| 52-Week Range | 0.2080 - 0.5300 |
| Beta | n/a |
| RSI | 64.40 |
| Earnings Date | Jun 24, 2026 |
About IGC Pharma
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi... [Read more]
Financial Performance
In fiscal year 2025, IGC Pharma's revenue was $1.27 million, a decrease of -5.50% compared to the previous year's $1.35 million. Losses were -$7.12 million, -45.22% less than in 2024.
Financial numbers in USD Financial StatementsNews
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE Ame...
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion POTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma...
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
POTOMAC, MD / ACCESS Newswire / April 14, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it has approximately 80% patient enrollment in its Phase 2 CALMA cli...
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
POTOMAC, MD / ACCESS Newswire / April 8, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company with its lead program currently in a Phase 2 CALMA...
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
POTOMAC, MD / ACCESS Newswire / April 7, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing innovative treatments for Alzheimer's d...
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
POTOMAC, MD / ACCESS Newswire / March 30, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
- Strategic Pivot to Pure-Play Biotech - POTOMAC, MD / ACCESS Newswire / March 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developi...
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
POTOMAC, MD / ACCESS Newswire / February 26, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's diseas...
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
POTOMAC, MARYLAND / ACCESS Newswire / February 24, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Ascendiant Capital Markets has issued an updated equity re...
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
- Practice integrated neurology network expands enrollment capacity - POTOMAC, MARYLAND / ACCESS Newswire / February 23, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today ann...
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
POTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a ...
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
POTOMAC, MD / ACCESS Newswire / February 12, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating i...
IGC Pharma Announces Equity Research Update by Alliance Global Partners
POTOMAC, MARYLAND / ACCESS Newswire / February 10, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that Alliance Global Partners ("AGP") has published an updated ...
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst - POTOMAC, MARYLAND / ACCESS Newswire / February 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC...
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
POTOMAC, MARYLAND / ACCESS Newswire / February 2, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today reported it has reached approximately 70% of planned patient enrollment in...
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study - POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE Ameri...
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
- Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (N...
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligen...
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC...
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
- New Patent Expands IGC Pharma's Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer's Disease - POTOMAC, MD / ACCESS Newswire / December 19, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or t...
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) ...
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.
POTOMAC, MD / ACCESS Newswire / December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to dev...
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) t...
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation POTOMAC, MD / ACCESS Newswire / December 2, 2025 / IGC Pharma, Inc. (NYSE America...